Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04276441 · ClinicalTrials.gov registry record
A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World
A clinical trial, sponsored by Janssen Scientific Affairs.
- Completed
- Registry status
- 34,244
- Enrollment target
NCT04276441: Completed study, sponsored by Janssen Scientific Affairs.
NCT04276441 is a clinical trial that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 34,244 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04276441 has completed, sponsored by Janssen Scientific Affairs.
- COMPLETED
- Registry status
- 34,244 participants
- Enrollment target
Study Summary
The primary objectives of this study are to identify and diagnose Atrial Fibrillation (AF), evaluate improvement in cardiovascular (CV) outcomes, improve direct oral anti-coagulant (DOAC) adherence and persistence, and better characterize participants and identify predictors of disease.
Primary Outcome
Time to a clinical diagnosis of AF obtained from healthcare claims database.
Interventions
- DEVICE Heart healthy Engagement Program with the Apple Watch Series 5 or later
- DEVICE Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34,244 participants |
| Start Date | 2020-02-25 |
| Est. Completion | 2025-01-23 |
What the finished NCT04276441 record still lists
NCT04276441 is an observational study that tracks outcomes without assigning an intervention. Its 34,244 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Heart healthy Engagement Program with the Apple Watch Series 5 or later is the first listed.
NCT04276441 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04276441 about?
NCT04276441 is a clinical study titled "A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World". The primary objectives of this study are to identify and diagnose Atrial Fibrillation (AF), evaluate improvement in cardiovascular (CV) outcomes, improve direct oral anti-coagulant (DOAC) adherence and persistence, and better characterize participants and identify predictors of disease.
What is the current status of trial NCT04276441?
This trial is currently completed. The enrollment target is 34,244 participants. The study started on 2020-02-25. Estimated completion is 2025-01-23.
What interventions are being tested in trial NCT04276441?
The interventions under investigation include: Heart healthy Engagement Program with the Apple Watch Series 5 or later (DEVICE), Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later (DEVICE).
Who is sponsoring clinical trial NCT04276441?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03720613 · 34,532 participants
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
- NCT02225301 · 35,000 participants · NA
iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers
- NCT06145724 · 33,183 participants · NA
EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 1)
- NCT04477928 · 33,000 participants
General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI